Lazertinib: First Approval
2021/05/24 by Sohita Dhillon · 94 citations
Chemistry · Medicine · #Cancer #Cancer research #Epidermal growth factor receptor #Gefitinib #Internal medicine #Lung Cancer Research Studies #Lung Cancer Treatments and Mutations #Lung cancer #Medicine #Oncology #Pharmacology #Quinazolinone synthesis and applications #Receptor #T790M #Tyrosine kinase #Tyrosine-kinase inhibitor
paper · pdf · doi:10.1007/s40265-021-01533-x
published in Drugs 81(9), 1107-1113 (Adis, Springer Healthcare)
openalex publication_date 2021/05/24 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
Abstract
) is an oral, third-generation, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) being developed by Yuhan and Janssen Biotech for the treatment of non-small cell lung cancer (NSCLC). It is a brain-penetrant, irreversible EGFR-TKI that targets the T790M mutation and activating EGFR mutations Ex19del and L858R, while sparing wild type-EGFR. In January 2021, lazertinib received its first approval for the treatment of patients with EGFR T790M mutation-positive locally advanced or metastatic NSCLC who have previously received EGFR-TKI therapy. This article summarizes the milestones in the development of lazertinib leading to this first approval.
Cited by
- Role of protein phosphorylation in cell signaling, disease, and the intervention therapy. [europepmc]
- Treatment Patterns, Clinical Outcomes and Health Care Resource Utilisation in Patients with EGFR-mutated Metastatic Non-Small Cell Lung Cancer: A Real-World Study in South Korea. [europepmc]
- Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. [europepmc]
- Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer. [europepmc]
- Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448). [europepmc]
- Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review. [europepmc]
- Small Molecule Inhibitors as Therapeutic Agents Targeting Oncogenic Fusion Proteins: Current Status and Clinical. [europepmc]
- The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies. [europepmc]
- Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications. [europepmc]
- Synthetic Routes and Clinical Application of Representative Small-Molecule EGFR Inhibitors for Cancer Therapy. [europepmc]
- MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting? [europepmc]
- Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy. [europepmc]
- Comparative effectiveness of lazertinib in patients with EGFR T790M-positive non-small-cell lung cancer using a real-world external control. [europepmc]
- Lazertinib in EGFR-Variant Non-Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial. [europepmc]
- Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFR T790M/C797S/L858R and EGFR T790M/L858R . [europepmc]
- Next-generation EGFR tyrosine kinase inhibitors to overcome C797S mutation in non-small cell lung cancer (2019-2024). [europepmc]
- Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer. [europepmc]
- Lazertinib: breaking the mold of third-generation EGFR inhibitors. [europepmc]
- Reciprocal regulation of MMP-28 and EGFR is required for sustaining proliferative signaling in PDAC. [europepmc]
- New Treatment Strategies in Advanced Epidermal Growth Factor Receptor-Driven Non-Small Cell Lung Cancer: Beyond Single Agent Osimertinib. [europepmc]
- A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024. [europepmc]
- Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR-Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study. [europepmc]
- Multidrug Resistance: Are We Still Afraid of the Big Bad Wolf. [europepmc]
- The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast. [europepmc]
- Non-small cell lung cancer after EGFR-TKI resistance: from drug resistance mechanisms to precision interventions. [europepmc]
Related